Lobeglitazone, another PPARγ agonist, also leads to moderate weight gain and attenuates hepatic steatosis, with an improvement of glucose and lipid homeostasis in patients with T2D; however, more randomized controlled trials must be conducted to further assess the effects of lobeglitazone [109]. This evidence concerns the gene PPARG and Hepatic steatosis.